Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Twist Bioscience Corp

NASDAQ: TWST · Life Sciences · 17 alerts · CIK 1581280

Share price
$105.04Close, Nov 16
Market cap
$7.16B
Shares outstanding
68.18MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Twist Bioscience Corp filings on SEC EDGAR ↗

4:30 PM ET 10-K
Financial Results

Twist Bioscience FY 2026 Results: Net Loss of $130M, Loss Widens

Twist Bioscience reported net proceeds of approximately $327.7 million from an August 2026 public offering and $97.1 million from an at-the-market program. Despite these capital raises, the company anticipates continued net losses and negative free cash flows for the near future while expanding international operations, which accounted for 41% of revenue in fiscal 2026.

Key figure
Net loss $130M
7:20 AM ET 8-K
Financial Results

Twist Bioscience Financial Results

Twist Bioscience reported record fiscal 2026 revenue of $459.4 million, a 22% increase year-over-year, driven by strong growth in DNA Synthesis and NGS Applications. The company achieved positive adjusted EBITDA in the fourth quarter and improved its annual gross margin to 52.4%. Management issued fiscal 2027 revenue guidance of $550 million to $560 million, representing approximately 21% growth at the midpoint.

Term
FY2026

“Fiscal 2026 demonstrated what Twist can deliver: strong top line revenue growth, expanded gross margin and positive adjusted EBITDA in the fourth quarter, all while continuing to broaden our capabilities and strengthen our balance sheet.”

Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience

“We enter fiscal 2027 with a stronger business and the capital to invest in our next phase of growth. AI is expanding what scientists can design, and personalized medicine is increasing the demand for unique molecules. Both play directly to our strength of customization at scale.”

Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.